However, despite the significant rise, plasma ketone body concentrations remained within moderate ranges, and no cases of diabetic ketoacidosis were observed, which is a crucial finding in terms of safety concerning SGLT2 inhibitors in type 1 diabetes. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.